Last Updated on September 2, 2025 by The Health Master
NPPA
Download NPPA notification No. S.O. 3563(E) dt 01-08-2025, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 37 formulations under the Drugs (Prices Control) Order, 2013, vide S.O. 3563 (E) dt 01-08-2025 based on the decision of 135th Authority meeting dated 30-07-2025.
The notification states as follows:
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
A table is given below the article
Note:
(a) The manufacturer of the above-mentioned formulations, i.e., the “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have actually paid it or it is payable to the Government on the retail price mentioned in column (6) of the above-mentioned table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013.
The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above, i.e., those who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to the fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes or rules, including manufacturing license permission from the competent authority, i.e., the central or state licensing authority, as may be applicable, by the concerned manufacturer/marketing company.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer / marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of the manufacturer and marketing company specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer and marketing company Companies as specified in corresponding entries in Columns (2), (3), and (5) thereof, if any, issued prior to this notification, stand superseded.

Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
NPPA updated price lists: Download
Latest Notifications: EC Act (Essential Commodities Act)
NPPA fixed Ceiling price of 4 scheduled formulations: August 2025
NPPA directs Pharma industry on MRP of Non-Scheduled Formulations
NPPA fixed retail price of 71 formulations: July 2025
NPPA fixed retail price of 41 formulations: June 2025
NPPA revised Ceiling price of 748 scheduled formulations: March 2025
New prices of Coronary Stents in India effective from April 2025
NPPA fixed Ceiling price of 4 scheduled formulations: August 2025
Drug Imports: New Online System for Dual Use NOC launched
FSSAI: Food Labelling and Display – Chapter-20
USFDA inspection: At Torrent Pharma with zero observations at Vizag
Govt. appoints Adnl. DGHS as the Compounding Authority
USFDA inspection: At Granules India arm with 1 observation
Amendment: Know About the Cosmetics (Amendment) Rules, 2025
USFDA inspection: At Senores Pharma arm with 3 observations
Drug recall: Sun Pharma, Lupin, Dr. Reddy’s recall drugs
Ranitidine Under Scrutiny Over NDMA Concerns
NPPA directs Pharma industry on MRP of Non-Scheduled Formulations
Table
| Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1 | Aceclofenac, Paracetamol & Trypsin Chymotrypsin Tablets | Each enteric coated tablet contains: Proteolytic enzymes Trypsin & Chymotrypsin in the ratio of Approximately 6:1 and provides enzymatic activity Eq. to 1,50,000 Armour units Aceclofenac IP 100 mg Paracetamol IP 325 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Dr. Reddy’s Laboratories Ltd. | 13.00 |
| 2 | Aceclofenac, Paracetamol & Trypsin Chymotrypsin Tablets | Each enteric coated tablet contains: Proteolytic enzymes Trypsin & Chymotrypsin in the ratio of Approximately 6:1 and provides enzymatic activity Eq. to 1,50,000 Armour units Aceclofenac IP 100 mg Paracetamol IP 325 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Cadila Pharmaceuticals Ltd. | 15.01 |
| 3 | Amoxycillin & Potassium Clavulanate Oral suspension | Each 5 ml of reconstituted suspension contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 600 mg Potassium Clavulanate Diluted IP equivalent to Clavulanic Acid 42.9 mg | 1 ml | M/s Copmed Pharmaceuticals Pvt. Ltd./ M/s Zydus Healthcare Ltd. | 3.32 |
| 4 | Atorvastatin & Clopidogrel Tablets | Each uncoated bilayered tablet contains: Atorvastatin Calcium IP Equivalent to Atorvastatin 40 mg Clopidogrel Bisulphate IP equivalent to Clopidogrel 75 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Lupin Ltd. | 25.61 |
| 5 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 10 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd. | 19.86 |
| 6 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 20 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd. | 30.10 |
| 7 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 40 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd. | 30.47 |
| 8 | Atorvastatin Calcium and Clopidogrel Capsules | Each hard gelatin capsule contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg (As pellets) Clopidogrel Bisulphate IP equivalent to Clopidogrel 75mg (As pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd./ M/s Alkem Laboratories Ltd. | 15.94 |
| 9 | Atorvastatin, Clopidogrel and Aspirin Capsules | Each hard gelatin capsule contains: Atorvastatin Calcium IP Eqv. to Atorvastatin 10 mg (As Pellets) Clopidogrel Bisulphate İP Eq. to Clopidogrel 75 mg (As Pellets) Aspirin IP 75 mg (As enteric coated Pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd./ M/s Aristo Laboratories Pvt. Ltd. | 5.88 |
| 10 | Atorvastatin, Clopidogrel and Aspirin Capsules | Each hard gelatin capsule contains: Atorvastatin Calcium IP Eqv. to Atorvastatin 20 mg (As Pellets) Clopidogrel Bisulphate IP Eq. to Clopidogrel 75 mg (As Pellets) Aspirin IP 75 mg (As enteric coated Pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd./ M/s Aristo Laboratories Pvt. Ltd. | 8.33 |
| 11 | Bilastine & Montelukast Tablet | Each film coated bilayered tablet contains: Bilastine IP 40 mg Montelukast Sodium IP eq. to Montelukast 10 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Lupin Ltd. | 22.78 |
| 12 | Bisoprolol Fumarate & Amlodipine Tablets | Each film coated tablet contains: Bisoprolol Fumarate IP 2.5 mg Amlodipine Besylate IP equivalent to Amlodipine 5 mg | 1 Tablet | M/s Swiss Garnier Life Sciences/ M/s Cadila Pharmaceuticals Ltd. | 6.70 |
| 13 | Cefixime Oral Suspension (Combipack) | One Combipack contains: Part (A) Each 5ml of reconstituted suspension contains: Cefixime IP equivalent to Cefixime Anhydrous 200 mg Part (B) Each ampoule contains Sterile Water for Injection IP 25ml | 1 ml | M/s Alps Communication Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd. | 3.72 |
| 14 | Cefixime, Dicloxacillin (CR) and Lactic Acid Bacillus Tablets | Each film coated tablet contains: Cefixime IP as Trihydrate Eq. to Anhydrous Cefixime 200mg Dicloxacillin Sodium IP Eq. to Dicloxacillin 500 mg (Controlled release) Lactic Acid Bacillus 2.5 Billion Spores (Appropriate Overages of Lactic Acid Bacillus Spores Added) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Alkem Laboratories Ltd. | 15.25 |
| 15 | Cholecalciferol Oral Drops | Each ml contains: Cholecalciferol (Vitamin D3) IP 800 IU (as Stabilized) | 1 ml | M/s Ravenbhel Biotech/ M/s Zydus Healthcare Ltd. | 6.11 |
| 16 | Cilnidipine & Telmisartan Tablets | Each film coated tablet contains: Cilnidipine IP 20 mg Telmisartan IP 40 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Lupin Ltd. | 14.51 |
| 17 | Diclofenac Sodium, Paracetamol & Chlorzoxazone Tablets | Each uncoated tablet contains: Diclofenac Sodium IP 50 mg Paracetamol IP 325 mg Chlorzoxazone USP 250 mg | 1 Tablet | M/s Innova Captab Ltd./ M/s Dr. Reddys Laboratories Ltd. | 6.03 |
| 18 | Escitalopram Oxalate & Clonazepam Tablets | Each Film Coated Tablet Contains: Escitalopram Oxalate IP eq.to Escitalopram 5 mg Clonazepam IP 0.25 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Abbott Healthcare Pvt. Ltd. | 8.38 |
| 19 | Paracetamol, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Tablets | Each uncoated tablet contains: Paracetamol IP 500 mg Phenylephrine Hydrochloride IP 10 mg Chlorpheniramine Maleate IP 2 mg | 1 Tablet | M/s East African (I) Overseas / M/s Troikaa Pharmaceuticals Ltd. | 5.15 |
| 20 | Empagliflozin, Linagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg Linagliptin 5 mg Metformin Hydrochloride IP 1000 mg (as extended release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Corona Remedies Pvt. Ltd. | 33.13 |
| 21 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Metformin Hydrochloride IP 1000 mg (as extended release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s USV Ltd. | 27.50 |
| 22 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Metformin Hydrochloride IP 1000 mg (as extended release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Micro Labs Ltd. | 16.50 |
| 23 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Metformin Hydrochloride IP 1000 mg (as extended release) | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Aristo Pharmaceuticals Pvt. Ltd. | 17.42 |
| 24 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Empagliflozin 10 mg Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Metformin Hydrochloride IP 1000 mg (as extended release) | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Aristo Pharmaceuticals Pvt. Ltd. | 14.74 |
| 25 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Eris Lifesciences Ltd. | 18.70 |
| 26 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Medley Pharmaceuticals Ltd. | 13.40 |
| 27 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Medley Pharmaceuticals Ltd. | 14.30 |
| 28 | Sitagliptin + Pioglitazone + Metformin Hydrochloride (Sustained Release) Tablets | Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP (as sustained release form) 500mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Workcell Solutions Pvt. Ltd. | 14.11 |
| 29 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP 64.25 mg equivalent to Sitagliptin 50 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Tristar Formulations Pvt. Ltd/ M/s Franco Indian Pharmaceuticals Pvt. Ltd. | 11.16 |
| 30 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP 64.25 mg equivalent to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Tristar Formulations Pvt. Ltd/ M/s Franco Indian Pharmaceuticals Pvt. Ltd. | 12.59 |
| 31 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Primus Remedies Pvt. Ltd. | 12.19 |
| 32 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Aristo Pharmaceuticals Pvt. Ltd. | 11.52 |
| 33 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Primus Remedies Pvt. Ltd. | 13.87 |
| 34 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Aristo Pharmaceuticals Pvt. Ltd. | 14.69 |
| 35 | Paracetamol, Phenylephrine HCl, Chlorpheniramine Maleate suspension | Each 5 ml contains: Paracetamol IP 250 mg Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg | 1 ml | M/s Res-Sancta Limited / M/s Biological E. Limited | 0.71 |
| 36 | Paracetamol, Phenylephrine HCl, Chlorpheniramine Maleate, Ammonium Chloride, Sodium Citrate & Menthol suspension | Each 5ml (teaspoonful) contains: Paracetamol IP 250 mg Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg Ammonium Chloride IP 120 mg Sodium Citrate IP 60 mg Menthol IP 1 mg | 1 ml | M/s Windlas Biotech Limited / M/s Biological E. Limited | 0.41 |
| 37 | Diclofenac Injection | Each ml contains: Diclofenac Sodium IP 75 mg | 1ml | M/s Nitin Lifesciences Ltd. /M/s. Mankind Prime Labs Pvt. Ltd. | 31.77 |












